Headlines & Global News | FDA approves Celgene's Otezla for psioratic arthritis PharmaTimes Treatment for PSA, which affects about 30% of the 125 million people worldwide who have psoriasis, currently involves corticosteroids, disease-modifying antirheumatic drugs (DMARDs) and injectable tumour necrosis factor (TNF) inhibitors, notably AbbVie ... Celgene's Otezla is first oral therapy OKed by FDA for adults with active ... FDA Approves Otezla, New Medication For Psoriatic Arthritis FDA approves Celgene drug for psoriatic arthritis |
